Dual-Targeted Therapy With Upadacitinib and Ustekinumab in Pediatric Refractory Perianal Crohn's Disease. (PubMed, ACG Case Rep J) - Sep 30, 2026 - "No adverse events occurred. This case highlights dual UPA/UST therapy as a promising strategy for severe, refractory pCD in an adolescent."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics
|
|
Amelia Kellar; David Choi; Meredith Kline; Neha Sathe; Ranjana Gokhale
|